Xian Deli Biochemical Industry Co., Ltd. will participate in CPhI Europe 2025, which will be held from October 28–30, 2025, in Frankfurt, Germany.
Founded on August, 1999, Xian Deli Biochemicalis a high-tech enterprise specializing in the research, development, production, and sales of cyclodextrins and their derivatives, as well as active pharmaceutical ingredients (APIs).
For over 20 years, Deli Biochemical has adhered to the quality policy of “Focusing on excipients, quality first, integrity and service, striving for excellence.” Through continuous effort and innovation, the company has developed Hydroxypropyl Betadex (HPBCD) and Betadex Sulfobutyl Ether Sodium (SBECD), both of which have been publicly listed by the Center for Drug Evaluation (CDE) in China and registered with the U.S. FDA.
In addition to standard grades, the company also provides customized products tailored to specific customer requirements. With the evolving market environment, Deli Biochemical actively explores new products and technologies to meet emerging industry needs.
Recently, the company has developed new APIs including Glucosamine Sulfate Sodium Chloride Compound and Fumarate Vonoprazan, both of which have been filed with the CDE, while Menatetrenone (Vitamin K₂ analog) and Icodextrin have successfully completed pilot-scale production.
At this year’s CPhI Europe, our sales team will showcase our core cyclodextrin products and new APIs and intermediates, offering high-quality and reliable solutions to our global partners.
We sincerely invite all our valued customers and industry friends to visit ourbooth 8.0P30for discussion and cooperation.
We look forward to meeting you in Frankfurt!
Xian Deli Biochemical Industry Co., Ltd.
